Biogen (BUE:BIIB) FFO


BUE:BIIB Biogen Inc BUE:BIIB
63 GF Score
Price ARS25,760.00
GF Value ARS22,875.52
Valuation Modestly Overvalued
! 7 Warning Signs
View Full Analysis

What is Biogen FFO?

FFO (Funds from operations) only applies to REITs.

BUE:BIIB
63GF Score
Biogen Inc BUE:BIIB
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Biogen (BUE:BIIB) Overvalued in 2026?

Based on GuruFocus' analysis, Biogen stock appears to be overvalued. The current stock price of ARS25,760.00 is trading 12.6% above its estimated GF Value™ of ARS22,875.52. GuruFocus considers Biogen to be Modestly Overvalued.

Key valuation signals for BUE:BIIB:

  • FFO:
  • GF Value™: ARS22,875.52 vs. price of ARS25,760.00 (12.6% above fair value)
  • GF Score™: 63/100 with 7 warning signs

No single metric tells the full story. See the BUE:BIIB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Biogen Business Description

Address 225 Binney Street, Cambridge, MA, USA, 02142
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
63GF Score

Get the complete analysis for BUE:BIIB

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

ARS25,760.00
Price
ARS22,875.52
GF Value